 SEATTLE, Nov. 13, 2020 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS, a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the third quarter ended September 30, 2020, and provided an update on recent company developments. 